Table 1.
|
Secondary data |
Primary data |
95% Confidence interval |
Test-statistic |
|
---|---|---|---|---|---|
Variable-level | GER (θ1) | BCQDB (θ2) | Lower bound (θ2) | Upper bound (θ2) | p-value |
00-49 years |
21.4 |
24.4 |
19.4 |
30.1 |
ns |
50-69 years |
50.5 |
43.6 |
37.6 |
49.8 |
0.024 |
≥ 70 years |
28.1 |
32.0 |
26.4 |
37.9 |
ns |
pTis (non-invasive) |
4.3 |
4.5 |
2.4 |
7.7 |
ns |
pT1 (≤ 2cm) |
47.4 |
53.0 |
46.8 |
59.1 |
ns |
pT2 (≤ 5cm) |
35.8 |
30.8 |
25.3 |
36.8 |
ns |
pT3 (> 5cm) |
4.7 |
2.6 |
1.1 |
5.3 |
ns |
pT4 (involving other areals) |
7.8 |
9.0 |
5.9 |
13.1 |
ns |
pN+ |
37.0 |
32.7 |
27.1 |
38.7 |
ns |
Involved lymph nodes 0 |
60.9 |
63.4 |
57.0 |
69.6 |
ns |
Involved lymph nodes 1-3 |
20.1 |
19.3 |
14.5 |
24.9 |
ns |
Involved lymph nodes 4-9 |
11.8 |
10.5 |
6.9 |
15.1 |
ns |
Involved lymph nodes >10 |
7.2 |
6.7 |
3.9 |
10.7 |
ns |
Stage 0 |
4.2 |
4.5 |
2.4 |
7.7 |
ns |
Stage 1 |
36.0 |
38.7 |
32.8 |
44.9 |
ns |
Stage 2a |
28.5 |
27.8 |
22.5 |
33.6 |
ns |
Stage 2b |
16.4 |
12.0 |
8.4 |
16.6 |
ns |
Stage 3a |
4.2 |
2.3 |
0.8 |
4.8 |
ns |
Stage 3b |
6.3 |
8.6 |
5.6 |
12.7 |
ns |
Stage 4 |
4.5 |
6.0 |
3.5 |
9.6 |
ns |
Grading 1 (G1) |
11.3 |
7.9 |
4.9 |
11.9 |
ns |
Grading 2 (G2) |
55.8 |
43.3 |
37.1 |
49.6 |
<0.001 |
Grading 3 (G3) |
c32.9 |
48.8 |
42.5 |
55.1 |
<0.001 |
ERPR+ |
82.0 |
83.5 |
78.4 |
87.7 |
ns |
Variable-level |
GKR (θ1) |
BCQDB (θ2) |
Lower bound (θ2) |
Upper bound (θ2) |
p-value |
00-49 years |
20.4 |
24.4 |
19.4 |
30.1 |
ns |
50-69 years |
49.0 |
43.6 |
37.6 |
49.8 |
ns |
≥ 70 years |
30.6 |
32.0 |
26.4 |
37.9 |
ns |
Left side |
50.6 |
56.0 |
49.8 |
62.1 |
ns |
Right side |
47.7 |
44.0 |
37.9 |
50.2 |
ns |
Breast quadrant I |
48.6 |
46.6 |
40.5 |
52.8 |
ns |
Breast quadrant II |
12.3 |
11.3 |
7.7 |
15.7 |
ns |
Breast quadrant III |
9.1 |
11.7 |
8.1 |
16.1 |
ns |
Breast quadrant IV |
5.6 |
8.6 |
5.6 |
12.7 |
ns |
Multifocal |
16.6 |
17.3 |
12.9 |
22.4 |
ns |
Mamille |
7.8 |
4.5 |
2.4 |
7.7 |
0.045 |
Non-invasive tumor |
5.8 |
4.5 |
2.4 |
7.7 |
ns |
Stage 0 |
6.1 |
4.5 |
2.4 |
7.7 |
ns |
Stage 1 |
38.4 |
38.7 |
32.8 |
44.9 |
ns |
Stage 2 |
41.9 |
39.8 |
33.9 |
46.0 |
ns |
Stage 3 |
8.0 |
10.9 |
7.4 |
15.3 |
ns |
Stage 4 |
5.6 |
6.0 |
3.5 |
9.6 |
ns |
Stage 0 | 0–49 years |
7.0 |
7.7 |
2.5 |
17.0 |
ns |
Stage 1 | 0–49 years |
38.0 |
36.9 |
25.3 |
49.8 |
ns |
Stage 2 | 0–49 years |
43.7 |
46.2 |
33.7 |
59.0 |
ns |
Stage 3 | 0–49 years |
6.5 |
6.2 |
1.7 |
15.0 |
ns |
Stage 4 | 0–49 years |
4.8 |
3.1 |
0.4 |
10.7 |
ns |
Stage 0 | 50–69 years |
6.9 |
4.3 |
1.4 |
9.8 |
ns |
Stage 1 | 50–69 years |
39.4 |
41.4 |
32.3 |
50.9 |
ns |
Stage 2 | 50–69 years |
41.0 |
42.2 |
33.1 |
51.8 |
ns |
Stage 3 | 50–69 years |
7.7 |
6.9 |
3.0 |
13.1 |
ns |
Stage 4 | 50–69 years |
5.0 |
5.2 |
1.9 |
10.9 |
ns |
Stage 0 | ≥70 years |
4.1 |
2.4 |
0.3 |
8.2 |
ns |
Stage 1 | ≥70 years |
36.9 |
36.5 |
26.3 |
47.6 |
ns |
Stage 2 | ≥70 years |
42.2 |
31.8 |
22.1 |
42.8 |
ns |
Stage 3 | ≥70 years |
9.7 |
20.0 |
12.1 |
30.1 |
<0.001 |
Stage 4 | ≥70 years | 7.1 | 9.4 | 4.2 | 17.7 | ns |
(θ) Population parameter in percent, (GER) Mean of a five German regions for 1996–97 (Engel et al., 2002).
(BCQDB) Breast Cancer Query Database, Marburg, Germany; (GKR) Common Cancer Registers of the states.
Berlin, Brandenburg, Mecklenburg-Vorpommern, Saxony-Anhalt, Saxony and Thuringa (Stabenow & Eisinger, 2001).
(pN+) Pathological assessment of metastases in lymph nodes, (ERPR) Estrogen-Progesterone-Receptors.
(Multifocal) All quadrants involved, (Stage | age) Percent of patients with stage number conditional on age groups.